Drug Trial Radar · NCT03116594
Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over
Last checked: Nov 19, 2026Latest source record: Apr 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
675
Actual
Start
Jan 3, 2014
Primary completion
Apr 8, 2014
Study completion Mar 7, 2015
Sponsor
- Lead sponsor
- SK Chemicals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 17, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study assesses non-inferiority by comparing GMR(Geometric Mean Ratio) of NBP608 to Zostavax which are evaluated by gpELISA (Glycoprotein Enzyme Linked Immunosorbent Assay). Total of 646 healthy subjects aged 50 and over are enrolled, and each subject is administered with single dose of vaccine which is randomly assigned.
Conditions
- Herpes Zoster
Interventions
NBP608Biological
Preparation of Oka/SK strain of live, attenuated zoster virus
ZostavaxBiological
Preparation of Oka/Merck strain of live, attenuated zoster virus
Primary outcomes
What the sponsor says the trial is designed to measure.
- GMR(Geometric Mean Ratio) of VZV(Varicella-Zoster Virus) antibody titer measured by gpELISA(Glycoprotein Enzyme-Linked Immnosorbent Assay)Time frame: 6 weeks after IP(Investigational Product) vaccination
- GMR(Geometric Mean Ratio) ratio of NBP608 to Zostavax measured by gpELISA(Glycoprotein Enzyme-Linked Immnosorbent Assay)Time frame: 6 weeks after IP(Investigational Product) vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Korea University Guro Hospital
Seoul, Guro-gu, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.